Stockreport

CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Busines...

Cytosorbents Corporation  (CTSO) 
Last cytosorbents corporation earnings: 11/5 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: cytosorbents.com
PDF The De Novo medical device application for DrugSorbâ„¢-ATR is eligible for FDA priority review as an FDA Breakthrough Designated Device for this indicationThe Health Canad [Read more]